World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
49122
World Ranking
8771
National Ranking
296

Valter Torri publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Valter Torri sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 486 publications — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Valter Torri D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Valter Torri sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Valter Torri is affiliated with the Mario Negri Institute for Pharmacological Research in Italy. Their research primarily focuses on medicine, with significant contributions in oncology, pulmonary and respiratory medicine, cancer research, radiology, nuclear medicine and imaging, and molecular biology.

The scientist's recent work includes studies published between 2020 and 2022, addressing various aspects of cancer treatment and healthcare impacts related to COVID-19. Selected recent papers include:

  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, 2020, The Lancet Oncology
  • Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group, 2021, Radiotherapy and Oncology
  • Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials, 2020, The Lancet Oncology
  • Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial, 2022, Nature Medicine
  • Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial, 2020, ESMO Open

Frequent co-authors collaborating with Valter Torri include:

  • Marina Chiara Garassino
  • Roberto Ferrara
  • Eliana Rulli
  • Giuseppe Viscardi
  • Giuseppe Lo Russo

The scientist has published extensively in several notable venues, with the most frequent being:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Zenodo (CERN European Organization for Nuclear Research)
  • ESMO Open

Valter Torri's main fields of study underline a specialization in medicine, concentrated particularly on oncology and the study of thoracic and respiratory diseases. Subfields of particular focus are:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology

Their research topics cover a broad spectrum within cancer and related medical fields, including:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • COVID-19 and healthcare impacts
  • Gastric Cancer Management and Outcomes

Best Publications

  • Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

    Mahesh K. B. Parmar;Valter Torri;Lesley Stewart

  • Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Jean Pierre Pignon;Hélène Tribodet;Giorgio V. Scagliotti;Jean Yves Douillard

  • Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial

    Pierluigi Benedetti Panici;Stefano Basile;Francesco Maneschi;Andrea Alberto Lissoni

  • Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

    Daniel J. Sargent;Silvia Marsoni;Genevieve Monges;Stephen N. Thibodeau

  • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

    MK Parmar;JA Ledermann;N Colombo;Bois A Du

  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial

    Andrea Sartore-Bianchi;Livio Trusolino;Cosimo Martino;Katia Bencardino

  • Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

    Axel Grothey;Alberto F. Sobrero;Anthony F. Shields;Takayuki Yoshino

  • Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non–Small-Cell Lung Cancer

    Giorgio V. Scagliotti;Roldano Fossati;Valter Torri;Lucio Crinò

  • Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.

    R Fossati;C Confalonieri;V Torri;E Ghislandi

  • Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial

    M. K B Parmar;M. Adams;M. Balestrino;K. Bertelsen

  • Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

    Emmanuel Mitry;Anthony L.A. Fields;Harry Bleiberg;Roberto Labianca

  • Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials

    Roberto D’Amico;Silvia Pifferi;Cinzia Leonetti;Valter Torri

  • Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

    Andrés J M Ferreri;Kate Cwynarski;Elisa Pulczynski;Maurilio Ponzoni

  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

    Marina Chiara Garassino;Jennifer G. Whisenant;Li Ching Huang;Annalisa Trama

  • Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

    Marina Chiara Garassino;Olga Martelli;Massimo Broggini;Gabriella Farina

  • International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

    J Baptist Trimbos;Mahesh Parmar;Ignace Vergote;David Guthrie

  • Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care

    Alessandro Liberati;Roberto D'Amico;Silvia Pifferi;Valter Torri

  • Impact of Follow-up Testing on Survival and Health-Related Quality of Life in Breast Cancer Patients: A Multicenter Randomized Controlled Trial

    P. Ghezzi;S. Magnanini;M. Rinaldini;F. Berardi

  • Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Paolo G. Casali;Jean-Yves Blay;Alexia Bertuzzi;Stefan Bielack

  • Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente)

    E. Mari;I. Floriani;A. Tinazzi;A. Buda

Frequent Co-Authors

Marina Chiara Garassino
Marina Chiara Garassino University of Chicago
Roberto Labianca
Roberto Labianca Mario Negri Institute for Pharmacological Research
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Sandro Barni
Sandro Barni Mario Negri Institute for Pharmacological Research
Filippo de Braud
Filippo de Braud University of Milan
Salvatore Siena
Salvatore Siena University of Milan
Maurizio D'Incalci
Maurizio D'Incalci Humanitas University
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Andrea Sartore-Bianchi
Andrea Sartore-Bianchi University of Milan
Stefano Cascinu
Stefano Cascinu Vita-Salute San Raffaele University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative routes to a career in healthcare can open doors for students with diverse backgrounds and schedules. Online options have expanded rapidly, offering flexibility and accessibility to those unable to commit to traditional programs. For example, online adn programs for non nurses provide a valuable stepping stone for those interested in nursing but without prior experience in the field.

Beyond nursing, healthcare administration is another in-demand area. Many choose to fast-track their leadership goals by enrolling in online health administration programs, which offer accelerated pathways and specialized tracks.

Not all nursing schools require the TEAS or HESI entrance exams. For students seeking a less test-heavy admission process, there are nursing schools that don't require teas or hesi exams, making nursing more accessible.

For those interested in the administrative or technical side of medicine, choosing the best online medical billing and coding schools can offer fast entry into healthcare careers. With a variety of online degrees available, you can find the program that best fits your career ambitions and lifestyle.

Best Scientists Citing Valter Torri

Trending Scientists

Recently Published Articles